Legacy data sharing to improve drug safety assessment: the eTOX project,Nature Reviews Drug Discovery

当前位置： X-MOL 学术 › Nat. Rev. Drug. Disc. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Legacy data sharing to improve drug safety assessment: the eTOX project
Nature Reviews Drug Discovery ( IF 120.1 ) Pub Date : 2017-10-13 , DOI: 10.1038/nrd.2017.177
Ferran Sanz , , François Pognan , Thomas Steger-Hartmann , Carlos Díaz , Montserrat Cases , Manuel Pastor , Philippe Marc , Joerg Wichard , Katharine Briggs , David K. Watson , Thomas Kleinöder , Chihae Yang , Alexander Amberg , Maria Beaumont , Anthony J. Brookes , Søren Brunak , Mark T. D. Cronin , Gerhard F. Ecker , Sylvia Escher , Nigel Greene , Antonio Guzmán , Anne Hersey , Pascale Jacques , Lieve Lammens , Jordi Mestres , Wolfgang Muster , Helle Northeved , Marc Pinches , Javier Saiz , Nicolas Sajot , Alfonso Valencia , Johan van der Lei , Nico P. E. Vermeulen , Esther Vock , Gerhard Wolber , Ismael Zamora

The sharing of legacy preclinical safety data among pharmaceutical companies and its integration with other information sources offers unprecedented opportunities to improve the early assessment of drug safety. Here, we discuss the experience of the eTOX project, which was established through the Innovative Medicines Initiative to explore this possibility.

中文翻译：